Comparing 3 vs 5 day Terlipressin in Patients with Liver Cirrhosis presenting blood vomiting

THE EFFECT OF 3 DAYS VS 5 DAYS(STANDARD PROTOCOL) TERLIPRESSIN IN ACQUIRING HAEMOSTASIS AND PREVENTION OF REBLEEDING IN PATIENTS WITH ACUTE OESOPHAGEAL VARICEAL BLEED

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/11/022188

Enrollment

100

Registered

2019-11-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver Health Condition 2: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: Terlipressin,OGD scopy: Reducing the duration of administering Terlipressin(5 to 3) following Endoscopic band ligation. Route: IV infusion Dosage: 2mg/24hrs Duration: 3 days Control Int

Eligibility

Inclusion criteria

Inclusion criteria: All patients presenting with Acute Oesophageal Variceal bleeding. More than 18 years of age and up to 75 years of age. Both Male and Female will be included in the study. Patients with Cirrhosis and Portal Hypertension of any aetiology

Exclusion criteria

Exclusion criteria: Patients who continued to bleed on Day 1 and 2 Non variceal Bleeding Fundal varices Hepatorenal Syndrome GAVE Patients with contraindications to Terlipressin Less than 18 years of age and above 75 years of age

Design outcomes

Primary

Measure	Time frame
Rebleeding within 5 daysTimepoint: 3 days,5 days, 6 weeks	—

Secondary

Measure	Time frame
Rebleeding within 6 weeksTimepoint: Rebleeding within 6 weeks	—

Countries

India

Contacts

Public ContactDr Dinesh Jothimani

Rela Institue and Medical Centre

jdineshis@yahoo.co.uk9176599555

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026